References
- O’Neil J. Tackling drug-resistant infections globally: final report and recommendations (2016). https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf.
- European Centre for Disease Prevention and Control. Antimicrobial surveilance in Europe. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2015 (2017). https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/antimicrobial-resistance-europe-2015.pdf.
- Sörberg M, Farra A, Ransjö U et al. Differentl trends in antibiotic resistance rates at a university teaching hospital. Clin. Microbiol. Infect. 9(5), 388–396 (2003).
- McCann E, Kurtz S, Gupta V, Tabak Y. Positive correlation of carbapenem-non-susceptible Pseudomonas aeruginosa and Enterobacteriaceae rates in US hospitals. European Congress of Clinical Microbiology and Infectious Diseases. Madrid, Spain, 21–24 April 2018 ( Abstract O0129).
- Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg. Infect. Dis. 20(7), 1170–1175 (2014).
- Falagas ME, Tansarli GS, Rafailidis PI, Kapaskelis A, Vardakas KZ. Impact of antibiotic MIC on infection outcome in patients with susceptible Gram-negative bacteria: a systematic review and meta-analysis. Antimicrob. Agents Chemother. 56(8), 4214–4222 (2012).
- Kumar A, Roberts D, Wood KE et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit. Care Med. 34(6), 1589–1596 (2006).
- Shields RK, Anand R, Clarke LG et al. Defining the incidence and risk factors of colistin-induced acute kidney injury by KDIGO criteria. PLoS ONE 12(3), e0173286 (2017).
- Merchant S, Proudfoot EM, Quadri HN et al. Risk factors for Pseudomonas aeruginosa infections consequences of inappropriate initial antimicrobial therapy: a systematic literature review meta-analysis. J. Glob. Antimicrob. Resist. 14, 33–34 (2018) ( Epub ahead of print).
- Depestel D, Deryke A, Vikas V et al. Evaluating a combination antibiogram for Pseudomonas aeruginosa (PSA) blood/respiratory isolates from intensive care unit (ICU) and non-ICU settings across the United States (US). European Congress of Clinical Microbiology and Infectious Diseases. Madrid, Spain, 21–24 April 2018 ( Abstract O0131).
- Pogue J, Sanagaram R, Merchant S, Raina P, Puzniak L. Real world clinical experience with ceftolozane/tazobactam (C/T) for the treatment of complicated UTI tract infections (cUTI) and complicated intraabdominal infections (cIAI) due to Pseudomonas aeruginosa (PSA): an electronic medical record database review in the United States. European Congress of Clinical Microbiology and Infectious Diseases. Madrid, Spain, 21–24 April 2018 ( Abstract O0740).
- Castanheira M, Mills JC, Farrell DJ, Jones RN. Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals. Antimicrob. Agents Chemother. 58(11), 6844–6850 (2014).
- Van Duin D, Lok JJ, Earley M et al. Colistin versus ceftazidime–avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin. Infect. Dis. 66(2), 163–171 (2018).
- Lapuebla A, Abdallah M, Olafisoye O et al. Activity of imipenem with relebactam against Gram-negative pathogens from New York City. Antimicrob. Agents Chemother. 59(8), 5029–5031 (2015).
- Motsch J, De Oliveira C, Stus V et al. A multicenter, randomized, double-blind, comparator-controlled trial comparing the efficacy and safety of imipenem/relebactam versus colistin plus imipenem in patients with imipenem-non-susceptible bacterial infections. European Congress of Clinical Microbiology and Infectious Diseases. Madrid, Spain, 21–24 April 2018 ( Abstract O0427).
- Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob. Agents Chemother. 43(6), 1379–1382 (1999).
- Harris AD, Johnson JK, Thom KA et al. Risk factors for development of intestinal colonization with imipenem-resistant Pseudomonas aeruginosa in the intensive care unit setting. Infect. Control Hosp. Epidemiol. 32(7), 719–722 (2011).
- Feinstein M, Escandón-Vargas K, Reyes S, Hernández-Gómez C, Pallares CJ, Villegas MV. Improved outcomes when antibiotic prescribing guidelines are followed by healthcare providers: a Colombian example to encourage adherence in hospital settings. Infect. Control Hosp. Epidemiol. 32(7), 719–722 (2017).
- Hernández-Gómez C, Pallares CJ, Reyes S et al. Clinical impact of antimicrobial stewardship programs in Colombian acute care hospitals. Open Forum Infect. Dis. 4(Suppl. 1), S486 (2017).